Clinical Trials Directory

Trials / Conditions / Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

24 registered clinical trials studyying Advanced Biliary Tract Cancer — 5 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compar
NCT07265674
J-Pharma Co., Ltd.Phase 3
RecruitingA Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durv
NCT07229625
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
RecruitingA Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
NCT06978114
Sichuan Baili Pharmaceutical Co., Ltd.Phase 2
RecruitingGemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-I
NCT06988592
Fudan University—
RecruitingPhase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Re
NCT06708858
Dai, GuanghaiPhase 2
UnknownCadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer
NCT05820906
Tianjin Medical University Cancer Institute and HospitalPhase 2
UnknownOncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cance
NCT05823987
Fudan UniversityPhase 2
UnknownAnlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary
NCT05812430
The First Affiliated Hospital of Zhengzhou UniversityPhase 2
UnknownCryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously
NCT05781074
Fudan UniversityPhase 2
UnknownIBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
NCT05653180
Innovent Biologics (Suzhou) Co. Ltd.Phase 1 / Phase 2
UnknownEnvofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(E
NCT05410197
Sun Yat-sen UniversityPhase 2
Active Not RecruitingLenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Tre
NCT05170438
National Health Research Institutes, TaiwanPhase 2
Active Not RecruitingThe Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in T
NCT04781192
University of Kansas Medical CenterPhase 1 / Phase 2
TerminatedStudy of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
NCT05009953
CSPC Ouyi Pharmaceutical Co., Ltd.Phase 2
Active Not RecruitingCombination Immunotherapy in Rare Cancers Under InvesTigation
NCT04969887
Olivia Newton-John Cancer Research InstitutePhase 2
UnknownA Phase 1/2 Study of SC-43 in Combination With Cisplatin
NCT04733521
RaND BiosciencesPhase 1 / Phase 2
Active Not RecruitingPhase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer
NCT04727996
Seoul National University HospitalPhase 2
UnknownToripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
NCT04211168
Peking Union Medical College HospitalPhase 2
CompletedHAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
NCT04217954
Peking UniversityPhase 2
CompletedNGS as the First-line Treatment in Advanced Biliary Tract Cancer
NCT04172402
National Health Research Institutes, TaiwanPhase 2
Active Not RecruitingNAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
NCT04005339
Georgetown UniversityPhase 2
UnknownToripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer
NCT04027764
Dai, GuanghaiPhase 2
WithdrawnA Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507
NCT02597465
Sun Pharma Advanced Research Company LimitedPhase 3
CompletedPhase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliar
NCT03358849
Yonsei UniversityPhase 1